
|Articles|January 1, 2004
HIFU may offer advantages in PCa, but the jury is still out
Author(s)Michael O. Koch, MD
Over the last 20 years, radical retropubic prostatectomy has evolvedto become the standard of care in men with localized prostate cancer. Becauseof the morbidity of this procedure, however, interest has grown in the developmentof non-surgical modalities. Unfortunately, many of these non-surgical approaches,such as monotherapy with radioactive seed implantation, have resulted indisappointing results or excessive morbidity, as in first-generation cryotherapy.
Advertisement
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
European Commission approves subcutaneous pembrolizumab
2
Kim Nguyen Chi, MD, highlights patient-reported outcome data from AMPLITUDE
3
FDA grants 510(k) clearance to new edition of Focal One robotic HIFU
4
Microultrasonography positioned as alternative to MRI for image-guided prostate biopsy
5

















